Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NIO Inc. (NIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NIO Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while NIO Inc. trades at $4.87 (market cap $12.35B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.2× NIO Inc.'s market cap, and NIO Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NIO | |
|---|---|---|
Market Cap | $39.89B | $12.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $7.89 |
52-Week Low | $278.09 | $3.90 |
Enterprise Value | $38.15B | $11.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NIO trades at $4.78, unchanged on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but net losses persist at -$15.57B, though margins improved. Vehicle deliveries surged 62.9% year-over-year in June 2026, driven by strong ES9 performance. Cash flow remains negative, with a net cash outflow of -$10.87B in 2024.
The outlook is mixed: robust delivery growth and narrowing losses signal operational progress, but persistent cash burn and high debt pose risks. Analyst consensus leans bullish with 50% buy ratings, yet the stock faces headwinds from competitive pressures and macroeconomic concerns affecting Chinese EV stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
